JP2021500081A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500081A5
JP2021500081A5 JP2020543405A JP2020543405A JP2021500081A5 JP 2021500081 A5 JP2021500081 A5 JP 2021500081A5 JP 2020543405 A JP2020543405 A JP 2020543405A JP 2020543405 A JP2020543405 A JP 2020543405A JP 2021500081 A5 JP2021500081 A5 JP 2021500081A5
Authority
JP
Japan
Prior art keywords
cancer
granulocytes
vitro
cell
hematopoietic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500081A (ja
JP7674102B2 (ja
Filing date
Publication date
Priority claimed from GBGB1618106.7A external-priority patent/GB201618106D0/en
Application filed filed Critical
Publication of JP2021500081A publication Critical patent/JP2021500081A/ja
Publication of JP2021500081A5 publication Critical patent/JP2021500081A5/ja
Priority to JP2023011332A priority Critical patent/JP2023052704A/ja
Priority to JP2025054346A priority patent/JP2025114537A/ja
Application granted granted Critical
Publication of JP7674102B2 publication Critical patent/JP7674102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543405A 2016-10-26 2018-04-24 がんを殺傷する細胞 Active JP7674102B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023011332A JP2023052704A (ja) 2016-10-26 2023-01-27 がんを殺傷する細胞
JP2025054346A JP2025114537A (ja) 2016-10-26 2025-03-27 がんを殺傷する細胞

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1618106.7A GB201618106D0 (en) 2016-10-26 2016-10-26 Cancer-killing cells
PCT/GB2017/053222 WO2018078367A1 (en) 2016-10-26 2017-10-25 Cancer-killing cells
GBPCT/GB2017/053222 2017-10-25
PCT/GB2018/051073 WO2019081879A1 (en) 2016-10-26 2018-04-24 CELLS KILLING CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023011332A Division JP2023052704A (ja) 2016-10-26 2023-01-27 がんを殺傷する細胞

Publications (3)

Publication Number Publication Date
JP2021500081A JP2021500081A (ja) 2021-01-07
JP2021500081A5 true JP2021500081A5 (https=) 2021-05-20
JP7674102B2 JP7674102B2 (ja) 2025-05-09

Family

ID=57738294

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543405A Active JP7674102B2 (ja) 2016-10-26 2018-04-24 がんを殺傷する細胞
JP2023011332A Pending JP2023052704A (ja) 2016-10-26 2023-01-27 がんを殺傷する細胞
JP2025054346A Pending JP2025114537A (ja) 2016-10-26 2025-03-27 がんを殺傷する細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023011332A Pending JP2023052704A (ja) 2016-10-26 2023-01-27 がんを殺傷する細胞
JP2025054346A Pending JP2025114537A (ja) 2016-10-26 2025-03-27 がんを殺傷する細胞

Country Status (11)

Country Link
US (5) US11642373B2 (https=)
EP (3) EP3910056A1 (https=)
JP (3) JP7674102B2 (https=)
CN (1) CN111278968A (https=)
AU (5) AU2017349462B2 (https=)
CA (1) CA3115435A1 (https=)
DK (1) DK3532609T3 (https=)
ES (1) ES2886632T3 (https=)
GB (1) GB201618106D0 (https=)
IL (4) IL316666B2 (https=)
WO (2) WO2018078367A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201618106D0 (en) * 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells
CN115094112A (zh) * 2022-06-06 2022-09-23 同济大学 一种抗癌效率、癌症进展与预后的标志物及方法
JP2026508019A (ja) * 2023-03-10 2026-03-09 リフト バイオサイエンシズ リミテッド 治療用組成物
WO2026062399A1 (en) 2024-09-19 2026-03-26 Lift Biosciences Ltd Granulocytes and granulocyte precursors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241855A (en) 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
CA2109729A1 (en) 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
WO1993025710A1 (en) * 1992-06-08 1993-12-23 Gen-Probe Incorporated Preparation of nucleic acid from mononuclear cells
US5846529A (en) 1993-08-23 1998-12-08 Nexell Therapeutics, Inc. Infusion of neutrophil precursors for treatment of neutropenia
WO1995010291A1 (en) 1993-10-08 1995-04-20 Cellpro Ii Methods for collection and cryopreservation of human granulocytes
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US5733541A (en) 1995-04-21 1998-03-31 The Regent Of The University Of Michigan Hematopoietic cells: compositions and methods
AU2002225959A1 (en) 2000-11-09 2002-05-21 Mayo Foundation For Medical Education And Research Absolute lymphocyte recovery and cancer survival
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2002951082A0 (en) 2002-08-30 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic cellular agents
EP1680080A4 (en) 2003-10-31 2007-10-31 3M Innovative Properties Co NEUTROPHILIC ACTIVATION THROUGH COMPOUNDS TO MODIFY THE IMMUNE RESPONSE
CN105168250B (zh) * 2004-10-25 2019-02-05 塞勒兰特治疗公司 增殖骨髓细胞群体的方法及其应用
US7811815B2 (en) 2004-11-15 2010-10-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic uses of allogeneic myeloid progenitor cells
AU2007278748B2 (en) 2006-07-24 2013-08-15 The University Of Queensland Method of producing a population of cells
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
RU2548741C2 (ru) 2009-03-05 2015-04-20 Макрокьюэ, Лтд. Активированная лейкоцитарная композиция
US9199028B2 (en) 2010-01-15 2015-12-01 Memorial Sloan-Kettering Cancer Center Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
US9862928B2 (en) 2010-12-03 2018-01-09 Regents Of The University Of Minnesota Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells
CN103215340A (zh) 2012-01-19 2013-07-24 江苏粒福特生物科技有限公司 一种新颖的粒细胞制备及其抗癌活性检测方法
RU2603079C2 (ru) 2015-03-16 2016-11-20 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ активации цитотоксических лимфоцитов человека
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells
WO2019147187A1 (en) 2018-01-26 2019-08-01 Agency For Science, Technology And Research Neutrophil subtypes
CN110755449A (zh) 2019-10-15 2020-02-07 南方科技大学 一种光调控嗜中性粒细胞在治疗癌症的药物中的应用
GB201918341D0 (en) 2019-12-12 2020-01-29 Lift Biosciences Ltd Cells for treating infections
GB201918313D0 (en) 2019-12-12 2020-01-29 Lift Biosciences Ltd Cells for treating cancer

Similar Documents

Publication Publication Date Title
Wang et al. Investigation of the roles of exosomes in colorectal cancer liver metastasis
Anton et al. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion
Wu et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties
Guo et al. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy
Patterson et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma
Bao et al. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells
CN103627673B (zh) 一种人脑胶质瘤细胞系及其建立方法和应用
Botchkina et al. Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2. 24
Liu et al. Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells
JP2021500081A5 (https=)
Liao et al. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells
CN101538554A (zh) 经耐受性筛选的肿瘤干细胞、其制法、应用和试剂盒及其抗原组合物、制法、应用和试剂盒
Spelat et al. A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells
JP2025114537A (ja) がんを殺傷する細胞
Ding et al. Comprehensive review of macrophage models: primary cells and immortalized lines across species
Zhang et al. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment
Xiong et al. HIF1α and HIF2α regulate non-small-cell lung cancer dedifferentiation via expression of Sox2 and Oct4 under hypoxic conditions
Medina et al. Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells
CN102168085A (zh) 抑制miR-130b基因表达的siRNA和表达载体及其在制备提高肝癌治疗效果的药物中的应用
Hannig et al. Control of leucocyte differentiation from embryonic stem cells upon vasculogenesis and confrontation with tumour tissue
Yin et al. Sodium citrate pretreatment enhances CAR-T cell persistence and anti-tumor efficacy through inhibition of calcium signaling
CN108704138A (zh) TGF-β1抑制剂和GM-CSF抑制剂与吉西他滨联合在制备治疗癌症药物中的用途
Tang et al. Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma
Sharrow et al. Tumor-Associated Macrophages Expand Chemoresistant, Ovarian Cancer Stem-Like Cells
Suraeva et al. Characteristics of Mel Ibr melanoma line subclone after treatment with chicken embryo extract